ASCO 2024

REVIEW UroToday

Viewing 1-20 of 142 articles

ASCO 2024: Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Model in Oligometastatic Castration-Sensitive Prostate Cancer, Including in Patients from the STOMP and ORIOLE Phase II Randomized Clinical Trials

ASCO 2024: What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?

ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options?

ASCO 2024: Using Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer

ASCO 2024: Artificial Intelligence and Deep Learning in Prostate Cancer Pathology

ASCO 2024: Artificial Intelligence: Innovation and Potential for Diagnostic Imaging in Prostate Cancer

ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

ASCO 2024: FGFR3 Alterations in Patients Who Develop Locally Advanced or Metastatic Urothelial Cancer, and Their Association with Tumor Subtype and Clinical Outcomes in Patients Treated with Erdafitinib Versus Pembrolizumab

ASCO 2024: Cost-Effectiveness Analysis of Contemporary First-Line Agents in Locally Advanced/metastatic Urothelial Carcinoma

ASCO 2024: Considerations in Treating and Palliating Variant Genitourinary Cancers Where No Standard of Care Exists

ASCO 2024: Age and Other Criteria Influencing Non-Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries

ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

ASCO 2024: Avelumab First Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Histological Subtypes

ASCO 2024: Prognostic Impact of Residual Cancer Burden on Long-Term Outcomes After Neoadjuvant Androgen Receptor Pathway Inhibitor and Radical Prostatectomy for High-Risk Localized Prostate Cancer: A Pooled Analysis of Phase 2 Trials

ASCO 2024: Patient-Centered Approaches to Improve Quality of Life and Mitigate the Adverse Effects of Androgen Deprivation Therapy

ASCO 2024: Debunking the Frailty-Sarcopenia-ADT Axis in Metastatic Prostate Cancer with Multicomponent Exercise: The FIERCE Trial

ASCO 2024: A Phase II Trial of Enzalutamide with 5-Alpha Reductase Inhibitors as an ADT–Sparing Approach for Older Men with CSPC

ASCO 2024: Bone Resorptive Agents and Their Appropriate Use and Timing

ASCO 2024: Impact of Alterations in Tumor Suppressor Genes on Survival Outcomes in Patients with De Novo mCSPC Cancer Receiving ADT with ARPI or Docetaxel

ASCO 2024: Discussion: The Needle in the Haystack: Finding Biomarkers in Kidney Cancer

1
2
3
4
5
6
7
8